Concizumab prophylaxis in patients with haemophilia A or B without inhibitors: efficacy and safety results from the primary analysis of the phase 3 explorer8 study
Pratima Chowdary, M.D.
The efficacy and safety results from the primary analysis of the phase 3 explorer8 study discussing concizumab prophylaxis in patients with hemophilia A or B without inhibitors is discussed in this presentation. Chowdary, M.D., presents results comparing use of concizumab versus no prophylaxis and previous prophylaxis. This presentation concludes the concizumab prophylaxis to be safe, well tolerated, and effective in reducing the annualized bleeding rate.